Boqing Wang
Impact in
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
-
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in
-
- Hepatocellular Carcinoma Treatment and Prognosis 4
-
- Ferroptosis and cancer prognosis 2
- Sarcoma Diagnosis and Treatment 1
- Co-authors
- Wei Zhao (3 shared papers)Tiebang Kang (4 shared papers)Yi Sang (3 shared papers)Yuanzhong Wu (3 shared papers)Ruhua Zhang (3 shared papers)Haibo Han (2 shared papers)Dan Liao (2 shared papers)Zhihua Tian (2 shared papers)
In The Last Decade
Boqing Wang
23 papers receiving 721 citations
Boqing Wang's Hit Papers
Peers
Comparison fields: 5 of 71
- Hepatology 254
- Cancer Research 122
- Oncology 111
- Molecular Biology 201
- Pathology and Forensic Medicine 47
Countries citing papers authored by Boqing Wang
This map shows the geographic impact of Boqing Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boqing Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boqing Wang more than expected).
Fields of papers citing papers by Boqing Wang
This network shows the impact of papers produced by Boqing Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boqing Wang. The network helps show where Boqing Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Boqing Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2023 | 362 |
| 2 | 2013 | 54 | |
| 3 | 2019 | 50 | |
| 4 | 2014 | 46 | |
| 5 | 2013 | 37 | |
| 6 | 2017 | 31 | |
| 7 | 2021 | 30 | |
| 8 | 2019 | 29 | |
| 9 | 2017 | 18 | |
| 10 | 2024 | 14 | |
| 11 | 2017 | 12 | |
| 12 | Urban Health Care Reform Initiative in China: Findings from Its Pilot Experiment in Zhengjiang City (1) | 1999 | 10 |
| 13 | 2017 | 7 | |
| 14 | 2021 | 7 | |
| 15 | 2023 | 7 | |
| 16 | 2019 | 4 | |
| 17 | 2019 | 4 | |
| 18 | 2016 | 3 | |
| 19 | 2020 | 3 | |
| 20 | [Clinicopathological and immunohistochemical features of pulmonary blastoma: analysis of 4 cases and review of the literature]. | 2007 | 2 |
About Boqing Wang
Boqing Wang is a scholar working on Hepatology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Cell Biology, having authored 27 papers that have together received 734 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (4 papers), RNA modifications and cancer (3 papers), MicroRNA in disease regulation (3 papers), Ferroptosis and cancer prognosis (2 papers), Cancer-related gene regulation (2 papers), Epigenetics and DNA Methylation (2 papers), Sarcoma Diagnosis and Treatment (1 paper) and Adhesion, Friction, and Surface Interactions (1 paper). The work is most often cited by research in Hepatology (254 citations), Cancer Research (122 citations), Oncology (111 citations), Molecular Biology (201 citations) and Pathology and Forensic Medicine (47 citations). Boqing Wang has collaborated with scholars based in China, Ethiopia and Serbia. Frequent co-authors include Wei Zhao, Tiebang Kang, Yi Sang, Yuanzhong Wu, Ruhua Zhang, Haibo Han, Dan Liao, Zhihua Tian, Jianjun Tang and Gang Wang. Their work appears in journals such as The Lancet, Future Oncology, Oncology Reports, Cryobiology and BioData Mining.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.